Jaypirca (pirtobrutinib)
An approved treatment for Mantle Cell Lymphoma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Pirtobrutinib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Pirtobrutinib
- Brand name
- Jaypirca
- Drug class
- BTK inhibitor (non-covalent)
- Manufacturer
- Eli Lilly and Company
- How it's taken
- Oral tablet once a day
A once-daily BTK inhibitor pill for adults whose mantle cell lymphoma came back or stopped responding after at least 2 lines of treatment, including another BTK inhibitor. The mantle cell lymphoma use is an accelerated approval based on response rate; Jaypirca is also approved for CLL and SLL.
We'll email you when Jaypirca's FDA label changes, when the FDA acts on it, and when new trials for Mantle Cell Lymphoma open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Pirtobrutinib fits
For mantle cell lymphoma after a covalent BTK inhibitor such as Calquence or Brukinsa. Jaypirca binds BTK without forming a permanent bond, and its trial enrolled people who had already taken a BTK inhibitor. Beqalzi and CAR T-cell therapy are also approved at this stage, and no trial has compared them.
How Pirtobrutinib works
Like other BTK inhibitors, pirtobrutinib blocks BTK, a signaling enzyme cancerous B cells need to grow. Unlike the covalent BTK inhibitors, it binds without forming a permanent bond, and it blocks both normal BTK and BTK carrying C481 mutations[1].
Side effects and safety
- Infections. Grade 3 or worse in 23% of 1,153 trial patients, most often pneumonia, fatal in 4.3%.
- Bleeding. Major bleeding in 3.1%, fatal in 0.3%.
- Low blood counts. Grade 3 or 4 low neutrophils in 26%, low platelets in 9% and low hemoglobin in 9%.
- Heart rhythm problems. Atrial fibrillation or flutter in 3.1%.
- Second cancers. In 10%, most often non-melanoma skin cancer (4.9%).
- Liver injury. Drug-induced liver injury has occurred; liver tests are checked during treatment.
- Pregnancy. Can harm an unborn baby; effective contraception is advised.
- Complete blood counts regularly
- Liver tests during treatment
- Signs of infection, bleeding and irregular heartbeat
- Skin checks for new skin cancers
Jaypirca has no boxed warning. Across 1,153 trial patients its label reports grade 3 or worse infections in 23% (most often pneumonia, 13%; fatal in 4.3%), major bleeding in 3.1% (fatal in 0.3%), grade 3 or 4 low neutrophils in 26%, atrial fibrillation or flutter in 3.1%, second cancers in 10% (most often non-melanoma skin cancer, 4.9%), liver injury, and harm to an unborn baby[1].
In the mantle cell lymphoma group of BRUIN, the most common side effects were fatigue (29%), musculoskeletal pain (27%), diarrhea (19%) and swelling (18%)[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Pirtobrutinib
The dose is 200mg by mouth once a day, at the same time each day, with or without food, until the lymphoma progresses or side effects become unacceptable[1]. Tablets are swallowed whole with water and never cut, crushed or chewed. A dose missed by more than 12 hours is skipped.
Availability and cost
Only available as the brand-name product.
Help paying for Jaypirca
With private insurance, the drugmaker's copay card can lower what you pay for Jaypirca. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 3 charity funds for Mantle Cell Lymphoma, 3 were open on October 26, 2026. Pick your insurance below to see which offers fit you.
- Copay help
Jaypirca Savings Card: people with commercial drug coverage for Jaypirca may pay as little as $0 for a 1-month fill, up to $10,600 per calendar year (lower if enrolled in a copay maximizer). People with government coverage are not eligible.
For: private insurance · source - Insurance and case manager help
Lilly Support Services answers coverage and support questions at 1-800-LillyRx (1-800-545-5979).
The official page does not say who qualifies. Ask the program. · source
Good to know: Terms confirmed on the Jaypirca savings page on November 2, 2026, including 14 fills a year and, for people in a copay maximizer, up to $25 a month and $350 a year. Lilly's patient assistance program application exists at oncologysupport.lilly.com; its terms are not recorded here.
Charity funds for Mantle Cell Lymphoma
- From a charity · Blood Cancer United (formerly The Leukemia & Lymphoma Society)Clinical Trials Co-Pay Fund (all blood cancers) fundOpen
Pays for: Insurance premiums and treatment-related copays, deductibles and coinsurance, up to $3,500 per year. Requires health insurance (any kind).
- From a charity · Blood Cancer United (formerly The Leukemia & Lymphoma Society)Patient Aid Program fundOpen
Pays for: One-time $100 stipend for non-medical expenses (transportation, food, housing, utilities); no income or insurance requirement, up to $100 per year.
The foundation says: “CURRENT FUND STATUS: Open. Fund is currently Open.” - From a charity · HealthWell FoundationMantle Cell Lymphoma fundOpen
Pays for: Prescription copays; Medicare Part B premiums, up to $8,500 per year. Requires health insurance (any kind).
Clinical trial results
In the single-arm BRUIN trial (NCT03740529), 120 adults with mantle cell lymphoma previously treated with a BTK inhibitor took Jaypirca 200mg a day. Half (50%) responded, 13% completely, after a median of 1.8 months, and responses lasted a median of 8.3 months, with an estimated median follow-up of 7.3 months[1]. The median age was 71.
Development history
Jaypirca is marketed by Eli Lilly. The FDA first approved Jaypirca on January 27, 2023 for relapsed or refractory mantle cell lymphoma after a BTK inhibitor[2], and later added CLL and SLL uses[1].
Explore Mantle Cell Lymphoma trials
Other Mantle Cell Lymphoma treatments
Common questions about Pirtobrutinib
▸What is Pirtobrutinib (Jaypirca)?
A once-daily BTK inhibitor pill for adults whose mantle cell lymphoma came back or stopped responding after at least 2 lines of treatment, including another BTK inhibitor. The mantle cell lymphoma use is an accelerated approval based on response rate; Jaypirca is also approved for CLL and SLL.
▸How does Pirtobrutinib work?
Like other BTK inhibitors, pirtobrutinib blocks BTK, a signaling enzyme cancerous B cells need to grow. Unlike the covalent BTK inhibitors, it binds without forming a permanent bond, and it blocks both normal BTK and BTK carrying C481 mutations[1].
▸What are the side effects of Pirtobrutinib?
Jaypirca has no boxed warning. Across 1,153 trial patients its label reports grade 3 or worse infections in 23% (most often pneumonia, 13%; fatal in 4.3%), major bleeding in 3.1% (fatal in 0.3%), grade 3 or 4 low neutrophils in 26%, atrial fibrillation or flutter in 3.1%, second cancers in 10% (most often non-melanoma skin cancer, 4.9%), liver injury, and harm to an unborn baby[1]. In the mantle cell lymphoma group of BRUIN, the most common side effects were fatigue (29%), musculoskeletal pain (27%), diarrhea (19%) and swelling (18%)[1].
▸How is Pirtobrutinib taken?
The dose is 200mg by mouth once a day, at the same time each day, with or without food, until the lymphoma progresses or side effects become unacceptable[1]. Tablets are swallowed whole with water and never cut, crushed or chewed. A dose missed by more than 12 hours is skipped.
▸Is Pirtobrutinib FDA approved?
Yes, Pirtobrutinib (Jaypirca) is FDA approved (2023) for the treatment of Mantle Cell Lymphoma.
▸Can Jaypirca work after another BTK inhibitor stopped working?
That is the group it was tested in. In BRUIN, all 120 adults with mantle cell lymphoma had already taken a BTK inhibitor[1].
Results: 50% responded, including 13% with a complete response, after a median of 1.8 months.
How long: responses lasted a median of 8.3 months, with an estimated median follow-up of 7.3 months.
Approval: accelerated, based on response rate, so continued approval may depend on a confirmatory trial.
Source: Jaypirca prescribing information, October 2026.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Eli Lilly via DailyMed · 2026-10-19. Jaypirca (pirtobrutinib) tablets prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801
- FDA. Jaypirca approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216059
- Eli Lilly. Jaypirca Savings Card and coverage. https://jaypirca.lilly.com/savings-support